2025-09-06 - Analysis Report
Okay, here's an analysis of Teladoc Health Inc. (TDOC) based on the data you provided.

## TDOC (Teladoc Health Inc.) Analysis

Teladoc Health Inc. is a telehealth company providing virtual healthcare services.

### 1. Performance vs. S&P 500 (VOO)

*   **TDOC Cumulative Return:** -63.05%
*   **VOO Cumulative Return:** 102.38%
*   **Absolute Divergence (TDOC - VOO):** -163.9%
*   **Relative Divergence:** 0.6

**Analysis:** TDOC has significantly underperformed the S&P 500. The absolute divergence indicates a substantial difference in cumulative returns.  The relative divergence of 0.6 suggests that TDOC's underperformance is near the lower end of its historical range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha  | Beta   | Cap(B) |
|------------|---------|--------|--------|--------|--------|
| 2015-2017  | 76.0%   | 60.6%  | 50.0%  | -0.0   | 6.2    |
| 2016-2018  | 128.0%  | 59.3%  | 110.0% | -0.0   | 8.8    |
| 2017-2019  | 176.0%  | 59.3%  | 147.0% | 0.4    | 14.8   |
| 2018-2020  | 237.0%  | 64.0%  | 217.0% | 0.1    | 35.3   |
| 2019-2021  | -83.0%  | 64.0%  | -132.0% | 0.1    | 16.2   |
| 2020-2022  | -295.0% | 81.3%  | -297.0% | 0.0    | 4.2    |
| 2021-2023  | -488.0% | 81.3%  | -506.0% | -0.6   | 3.8    |
| 2022-2024  | -111.0% | 81.3%  | -137.0% | -0.8   | 1.6    |
| 2023-2025  | -34.0%  | 75.5%  | -87.0%  | -0.8   | 1.4    |

**Analysis:**

*   **CAGR:**  Historical CAGR was strong from 2015-2020 but has been significantly negative in recent years, indicating a sharp decline in growth.
*   **MDD:** High Maximum Drawdown values consistently exceeding 59% reflect substantial volatility and risk.
*   **Alpha:**  The negative Alpha values from 2019 onwards suggest that TDOC has consistently underperformed its benchmark on a risk-adjusted basis.
*   **Beta:**  Beta values close to 0 in early years and negative values in recent years imply a weak or even inverse correlation with the market.
*   **Cap(B):** Market Cap has decreased significantly from 35.3B to 1.4B.

### 2. Recent Stock Price Movement

*   **Current Price:** 7.82
*   **Previous Close:** 7.63
*   **Change:** 2.49%
*   **5-day Moving Average:** 7.725
*   **20-day Moving Average:** 7.4763
*   **60-day Moving Average:** 7.7071

**Analysis:** The stock price is currently above its 5-day, 20-day, and 60-day moving averages, suggesting a short-term upward trend.  The recent 2.49% price increase indicates positive momentum.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.3322 (Low Risk)
*   **RSI:** 58.38
*   **PPO:** 0.6639
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.33)
*   **Recent (20-day) Relative Divergence Change:** 0.3 (+) - Short-term increase.
*   **Expected Return (%):** -10171.4 (vs. S&P 500, long-term)

**Analysis:**

*   **MRI:**  Indicates low market risk
*   **RSI:** An RSI of 58.38 is approaching overbought conditions, suggesting the recent upward momentum might be limited.
*   **PPO:** The PPO is positive, further supporting the short-term upward trend.
*   **Hybrid Signal:** Suggests a cautious buy signal.
*   **Relative Divergence Change:** Reinforces the short-term positive trend.
*   **Expected Return:** The extremely negative expected return suggests very poor long-term prospects compared to the S&P 500 based on current conditions. The recent price increase of 2.49% reinforces recent market volatitlity.

### 4. Recent News & Significant Events

*   **Negative Sentiment:** Articles from Motley Fool and StockStory suggest avoiding TDOC, highlighting it as a "beaten-down stock" and one that "falls short."
*   **Mixed Sentiment:**  One article mentions TDOC among risky stocks.
*   **Positive/Neutral Sentiment:** Other articles discuss TDOC's performance since the last earnings report and its leadership in the telehealth market. The appointment of a new Chief Revenue Officer at TruLegal, a related company, may have indirect positive implications.

**Analysis:**  The news is mixed, with a significant portion leaning negative, particularly from sources focusing on investment recommendations.  The positive news focuses on the broader telehealth market and past performance rather than current strengths.

### 4-2. Analyst Opinions

*   **Consensus:** Neutral (indicated by "- (~-)" because specific numbers were not provided, but the description suggests a lack of strong buy or sell recommendations)
*   **Target Price:** Average target price of $9.12 suggests potential upside from the current price of $7.82, but the range ($7.00 - $12.00) indicates considerable uncertainty.
*   **Recent Rating Changes:** No specific changes are provided.

**Analysis:** Analyst opinions are relatively neutral, with a modest potential upside based on target prices. However, the wide range of target prices reflects uncertainty about the stock's future performance.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-07-30 | -0.19 | 0.63 B$   |
| 2025-05-01 | -0.53 | 0.63 B$   |
| 2024-10-31 | -0.19 | 0.64 B$   |
| 2024-08-01 | -4.92 | 0.64 B$   |
| 2025-07-30 | -4.92 | 0.64 B$   |

**Analysis:**

*   **EPS:** TDOC has reported negative EPS for all listed quarters. While recent EPS figures (-0.19) appear improved compared to previous figures (-0.53 and -4.92), the company is still not profitable.
*   **Revenue:** Revenue has remained relatively stable around $0.63-0.64 billion, indicating consistent sales but no significant growth.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $0.63B    | 69.85%        |
| 2025-03-31 | $0.63B    | 68.73%        |
| 2024-12-31 | $0.64B    | 70.50%        |
| 2024-09-30 | $0.64B    | 71.94%        |
| 2024-06-30 | $0.64B    | 70.73%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2025-06-30 | $1.42B    | -2.30%   |
| 2025-03-31 | $1.43B    | -6.52%   |
| 2024-12-31 | $1.49B    | -3.25%   |
| 2024-09-30 | $1.51B    | -2.21%   |
| 2024-06-30 | $1.50B    | -55.77%  |

**Analysis:**

*   **Revenue:** Revenue is stable.
*   **Profit Margin:** High profit margins are maintained, typically around 70%, suggesting strong pricing power.
*   **Equity:** Declining equity suggests potential financial challenges.
*   **ROE:**  Negative ROE indicates the company is not generating profits from its equity. The significant drop in ROE for the quarter ending 2024-06-30 suggests a period of substantial losses.

### 7. Overall Analysis

Based on the provided data, TDOC presents a mixed picture:

*   **Negative Aspects:**  Significant underperformance compared to the S&P 500, negative EPS and ROE, declining equity, negative long-term expected return, and recent news articles with negative sentiment raise concerns about the company's future prospects. The negative alpha and beta values in recent years further underscore the underperformance and weak correlation with the market.
*   **Positive Aspects:**  Stable revenue, high-profit margins, and a recent short-term upward price trend offer some positive signals. The MRI indicates low overall market risk.
*   **Neutral Aspects:** Analyst opinions are largely neutral, with a modest potential upside based on target prices, but significant uncertainty.

**Conclusion:**

TDOC appears to be a high-risk investment. While there are some positive aspects, the numerous negative indicators suggest caution. The company's significant underperformance compared to the S&P 500, ongoing losses, and negative sentiment in recent news articles are concerning. A recent short-term price increase might present a trading opportunity, but the long-term outlook appears challenging. Investors should carefully consider these factors and conduct further research before investing in TDOC.
